TLDR:
- British Patient Capital has allocated €20mn to Earlybird Health II, the second healthcare fund of Earlybird Health.
- The investment supports British Patient Capital’s mandate to catalyse more private sector investment into the UK.
British Patient Capital, a UK government-owned investment firm, has committed €20mn to Earlybird Health II, the second healthcare fund of Earlybird Health. This is the first investment by British Patient Capital in a German-domiciled fund. The investment aligns with British Patient Capital’s mission to encourage more private sector investment in the UK and will support Earlybird Health in building out their healthcare investment strategy, particularly within the UK market. Earlybird Health is a Germany-based healthcare investment firm with a presence in London. The fund aims to predominantly invest in European healthcare companies that deliver positive patient outcomes, across all healthcare sectors including digital health, diagnostics, medical devices, research and development tools, and biopharma. It will invest in technologies at various stages of development, from early stage to advanced technologies nearing regulatory approval and commercialization.
“We are delighted to be investing in Earlybird Health to support them in building out their healthcare investment strategy, especially within the UK,” said Christine Hockley, Managing Director for Funds at British Patient Capital. “This investment aligns with our strategy of increasing the sources of capital to innovative breakthrough companies within the sector.”
“Innovation in the UK is second to none and is underpinned by world-class science,” added John Yianni, Partner at Earlybird Health. “We are committed to supporting the European startup ecosystem and fostering the development and growth of some of the world’s most exciting new companies who stand to positively impact the lives of millions of people across the globe in the future.”
